A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Necrobiosis Lipoidica Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Status Terminated

Clinical Trial Summary

This is a randomized, double blind, placebo controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 20 ulcerated NL patients who also meet other inclusion/exclusion criteria will be enrolled in the study. The primary objective of this study is to evaluate the efficacy of PCS499 as compared with placebo in ulcerated patients with Necrobiosis Lipoidica.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Necrobiosis Lipoidica

Clinical Trial Details

NCT number	NCT04800562
Study type	Interventional
Source	Processa Pharmaceuticals
Contact
Status	Terminated
Phase	Phase 2
Start date	April 12, 2021
Completion date	April 14, 2023

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04492618` - Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica	Phase 2
	Completed	`NCT03698864` - A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica	Phase 2